Phase II Study of Regorafenib as Maintenance Therapy

Summary

Multicenter double-blind placebo-controlled randomized Phase II study comparing regorafenib® to placebo, as maintenance therapy in metastatic soft-tissue non-adipocytic sarcomas experiencing stable disease or response after 6 cycles of doxorubicin-based chemotherapy as 1st line chemotherapy.

Timeline

Start

2019-05-15

Primary completion

2024-03-15

Completion

2024-09-26

Drugs

Indications